FEATURED NEWS
Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC. Read more
LATEST NEWS
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more
Dr. Karen Reckamp discusses the challenges that both patients and oncologists in the Los Angeles area experienced during the devastating fires. Read more
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations. Read more